London, UK - A substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial, which found that the angiotensin converting enzyme (ACE) inhibitor ramipril (Altace® - Monarch Pharmaceuticals) ...
“This oral liquid form of ramipril provides physicians with another option for treating patients.” “This FDA approval of VOSTALLY marks an important milestone in expanding treatment options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback